Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy

  • US 7,081,250 B2
  • Filed: 12/08/2003
  • Issued: 07/25/2006
  • Est. Priority Date: 04/26/2000
  • Status: Expired due to Term
First Claim
Patent Images

1. A method of treating with oxybutynin a human subject having overactive bladder, while minimizing an anticholinergic or antimuscarinic adverse drug experience associated with said oxybutynin treatment therapy comprising the step of:

  • administering as a transdermal patch, a composition comprising oxybutynin to said subject to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5;

    1 to about 5;

    1, wherein the metabolite of oxybutynin is N-desethyloxybutynin, and wherein the transdermal patch includes an effective amount of a permeation enhancer selected from the group consisting essentially of;

    fatty acids, fatty acid esters, fatty alcohols, fatty acid esters of lactic acid or glycolic acid, glycerol di-and monoesters, short chain alcohols, and mixtures thereof.

View all claims

    Thank you for your feedback